Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nithya Prasannan"'
Autor:
Nithya Prasannan, Bertina Dragunaite, Rens de Groot, Deepak Singh, Karen Vanhoorelbeke, Marie Scully
Publikováno v:
HemaSphere, Vol 7, p e3924819 (2023)
Externí odkaz:
https://doaj.org/article/58d1933445c74f06a4ccd5a7ac377d7f
Autor:
Nithya Prasannan, Marie Scully
Publikováno v:
Platelets, Vol 32, Iss 1, Pp 42-46 (2021)
Von Willebrand factor has a pivotal role in primary hemostasis. Its role in thrombotic microangiopathies (TMA), as well as cardiovascular disease, has been demonstrated. Thrombotic thrombocytopenic purpura (TTP), a thrombotic microangiopathy, is a li
Externí odkaz:
https://doaj.org/article/2834600e11474931b3ce4103f6858df9
Autor:
Nithya Prasannan, Mari Thomas, Matthew James Stubbs, John-Paul Westwood, Rens de Groot, Deepak Singh, Marie Scully
Publikováno v:
Blood.
The benefits of caplacizumab in acute immune mediated TTP (iTTP) are well established. We identified a delay in normalisation of ADAMTS13 activity (>30%) in a subgroup of caplacizumab treated patients which was not evident in the pre-caplacizumab era
Autor:
Andrew J. Doyle, Matthew J. Stubbs, Will Lester, Will Thomas, John‐Paul Westwood, Mari Thomas, Charles Percy, Nithya Prasannan, Marie Scully
Publikováno v:
British journal of haematologyREFERENCES. 198(2)
Rituximab, an anti-CD20 monoclonal antibody, can be used to treat immune thrombotic thrombocytopenic purpura (iTTP) during acute presentation or disease relapse. Undesirable side-effects include severe hypersensitivity reactions, particularly anaphyl
Autor:
Marie Scully, Nithya Prasannan
Publikováno v:
Platelets. 32:42-46
Von Willebrand factor has a pivotal role in primary hemostasis. Its role in thrombotic microangiopathies (TMA), as well as cardiovascular disease, has been demonstrated. Thrombotic thrombocytopenic purpura (TTP), a thrombotic microangiopathy, is a li
Publikováno v:
Primer on Nephrology ISBN: 9783030764180
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18901f3df4d5ca62002a9366fb568eb4
https://doi.org/10.1007/978-3-030-76419-7_75
https://doi.org/10.1007/978-3-030-76419-7_75
Autor:
Nithya Prasannan, Melissa Heightman, Toby Hillman, Emma Wall, Robert Bell, Anna Kessler, Lucy Neave, Andrew Doyle, Akshitha Devaraj, Deepak Singh, Hakim-Moulay Dehbi, Marie Scully
Publikováno v:
Blood advances. 6(13)
Post-COVID syndrome (PCS), or long COVID, is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance, chest pain, shortness of breath, and cognitive slowing. Acute COVID-1
Autor:
Arunodaya Mohan, Mairi Walker, Luke Carter-Brzezinski, Chris Peet, Yezenash Ayalew, Israa Kaddam, Rita Perry, David Tucker, Mac Macheta, Hayder Hussein, Suriya Kirkpatrick, Julia Wolf, Cristina Crossette-Thambiah, Sarah Wharin, Dianne Plews, Melek Akay, Graham McIlroy, Alexandros Rampotas, Lydia Wilson, Sarah Davis, Jesca Boot, Regina Nolan, Akila Danga, Dan Mei Xu, Tina T. Biss, Dominique Chan-Lam, Jennifer Swieton, Tanya Freeman, Claire Burney, Keir Pickard, Sheila Jen, Chloe Knott, Alvin Katumba, Sam Ackroyd, Edward Blacker, Beena Salhan, Richard Buka, Duncan Murray, Charlotte Bradbury, Sally Chown, Quentin A. Hill, Mohd Sharin Mohd Noh, Chira Mustafa, Nicola Crosbie, Surenthini Suntharalingam, Katja Kimberger, Rory McCulloch, Thomas Skinner, Naoimh Herlihy, Daire Quinn, Abbas Zaidi, Haroon Miah, Louise Garth, Eleana Loizou, Robert Dunk, Dan Halperin, Michael J R Desborough, Nithya Prasannan, Rupert Hipkins, Holly Gibson, Christopher McDermott, Amelia Fisher, Yogesh Upadhye, Sarah Wexler, Hina Peter, Sarah Jaafar, Sine Janum, Andrew J. Doyle, John Willan, Sree Sreedhara, Han Wang, Jonathan Kerr, Laura Aiken, Tom Bull, Seda Cakmak, Jennifer Darlow, Martin Besser, Michael Joffe, Benjamin Bailiff, Susan Robinson, Charlotte Wilding, Atiqa Miah, Jorge Cartier, Ryan Mullally, Miroslab Kmonicek, Samuel Harrison, Marquita Camillieri, Vickie MacDonald, Jane Graham, Ayesha Ejaz, Ipek Cakmak, Upekha Badaguma, Michelle Melly, Christopher Bailey, Belen Sevillano, Francesca Crolla, Frances Seymour, Indrani Venkatadasari, Laura Magill, Claire Lentaigne, Pamela Oshinyemi, Katherine Leighton, Maipelo Kgologolo, Zara Sayar, Elissa K. Dhillon, Lindsay McLeod-Kennedy, Sophie Hanina, Alice Thorpe, David Wright, Andrew Hastings, Caroline Shrubsole, Gillian C. Lowe, Nichola Cooper, Shivali Walia, Gulnaz Shah, Abi Martin, David Sharpe, Anna Dillon, Georgina Talbot, Imogen Swart-Rimmer, Phillip L R Nicolson, Paul Greaves, Olivia Kreze, Gemma Scott, Amir Shenouda, Edmund Watson, Shereef Elmoamly, Roochi Trikha, Wayne Thomas, Rebecca Pryor, Hafiz Qureshi, Laura Batey, Abigail Atkin, Dimitris Tsitsikas, Suthesh Sivapalaratnam, Hajer Oun
Publikováno v:
Clinical Medicine. 19(Suppl 3)
Intravenous immunoglobulin (IVIg) is a common therapy for patients with immune thrombocytopenia (ITP). The initial response rate for IVIg is 80%[1][1] and is typically rapid, with some patients responding in 24 hours, although usually in 2–4 days.[